Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4534-4539

  Rouan, Marie Claude ^a   Gevers, Tom ^a   Roymans, Dirk ^a   De Zwart, Loeckie ^b   Nauwelaers, David ^c   De Meulder, Marc ^b   Van Remoortere, Pieter ^a   Vanstockem, Marc ^a   Koul, Anil ^b   Simmen, Kenny ^a   Andries, Koen ^b  

^a TIBOTEC BVBA   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; TMC 353121; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COTTON RAT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; MALE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGMODONTINAE;

EID: 78049277866     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00643-10     Document Type: Article

References (28)

1. Andries, K., M. Moeremans, T. Gevers, R. Willebrords, C. Sommen, J. Lacrampe, F. Janssens, and P. R. Wyde. 2003. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. 60:209-219.
2. 99mTc-DTPA and urea for measuring cefepime concentrations in epithelial lining fluid. Eur. Respir. J. 24:150-156.
3. Bonfanti, J. F., C. Meyer, F. Doublet, J. Fortin, P. Muller, L. Queguiner, T. Gevers, P. Janssens, H. Szel, R. Willebrords, P. Timmerman, K. Wuyts, P. van Remoortere, F. Janssens, P. Wigerinck, and K. Andries. 2008. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J. Med. Chem. 51:875-896.
4. Byrd, L. G., G. A. Prince. 1997. Animal models of respiratory syncytial virus infection. Clin. Infect. Dis. 25:1363-1368.
5. Chanock, R., and L. Finberg. 1957. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am. J. Hyg. (Lond.) 66:291-300.
6. Chanock, R., B. Roizman, and R. Myers. 1957. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am. J. Hyg. (Lond.) 66:281-290.
7. Cianci, C., E. V. Genovesi, L. Lamb, I. Medina, Z. Yang, L. Zadjura, H. Yang, C. D'Arienzo, N. Sin, K.-L. Yu, K. Combrink, Z. Li, R. Colonno, N. Meanwell, J. Clark, and M. Krystal. 2004. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob. Agents Chemother. 48:2448-2454.
8. Cramer, H., J. R. Okicki, M. Kuang, and Z. Xu. 2005. Targeted therapy of respiratory syncytial virus by 2-5A antisense. Nucleosides Nucleotides Nucleic Acids 24:497-501. (Pubitemid 41440636)
9. Davis, C. B., T. W. Hepburn, J. J. Urbanski, D. C. Kwok, T. K. Hart, D. J. Herzyk, S. G. Demuth, M. Leland, and G. R. Rhodes. 1995. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab. Dispos. 23: 1028-1036.
10. Domachowske, J. B., C. A. Bonville, and H. F. Rosenberg. 2004. Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr. Infect. Dis. J. 23:S228-234.
11. Falsey, A. R., and E. E. Walsh. 2000. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 13:371-384.
12. Hall, C. B., K. R. Powell, N. E. MacDonald, C. L. Gala, M. E. Menegus, S. C. Suffin, and H. J. Cohen. 1986. Respiratory syncytial virus infection in children with immunocompromised immune function. N. Engl. J. Med. 315:77-81.
13. Hruska, J. F., P. E. Morrow, S. C. Suffin, and R. G. Douglas. 1982. In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob. Agents Chemother. 21:125-130.
14. Huntley, C. C., W. J. Weiss, A. Gazumyan, A. Buklan, B. Feld, W. Hu, T. R. Jones, T. Murphy, A. A. Nikitenko, B. O'Hara, G. Prince, S. Quartuccio, Y. E. Raifeld, P. Wyde, and J. F. O'Connell. 2002. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob. Agents Chemother. 46:841-847.
15. Kochhar, D. M., J. D. Penner, and T. B. Knudsen. 1980. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol. Appl. Pharmacol. 52:99-112.
16. Leader, S., and K. Kohlhase. 2002. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr. Infect. Dis. J. 21:629-632.
17. Leaman, D. W., F. J. Longano, J. R. Okicki, K. F. Soike, P. F. Torrence, R. H. Silverman, and H. Cramer. 2002. Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology 292:70-77.
18. Perkins, S. M., D. L. Webb, S. A. Torrance, C. El Saleeby, L. M. Harrison, J. A. Aitken, A. Patel, and J. P. DeVincenzo. 2005. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J. Clin. Microbiol. 43:2356-2362.
19. Prince, G. A., V. G. Hemming, R. L. Horswood, and R. M. Chanock. 1985. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 3:193-206.
20. Prince, G. A., A. B. Jenson, R. L. Horswood, E. Camargo, and R. M. Chanock. 1978. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am. J. Pathol. 93:771-791.
21. Roymans, D., H. L. De Bondt, E. Arnoult, P. Geluykens, T. Gevers, M. Van Ginderen, N. Verheyen, H. Kim, R. Willebrords, J. F. Bonfanti, W. Bruinzeel, M. D. Cummings, H. van Vlijmen, and K. Andries. 2010. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc. Natl. Acad. Sci. U. S. A. 107:308-313.
22. Schmidt, A. C. 2007. Progress in respiratory virus vaccine development. Semin. Respir. Crit. Care Med. 28:243-252.
23. Shay, D. K., R. C. Holman, R. D. Newman, L. L. Liu, J. W. Stout, and L. J. Anderson. 1999. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440-1446.
24. Simoes, E. A. F. 1999. Respiratory syncytial virus infection. Lancet 354:847-852.
25. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, and K. Fukuda. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186. (Pubitemid 36068705)
26. van Drunen Littel-van den Hurk, S., J. W. Mapletoft, N. Arsic, and J. Kovacs-Nolan. 2007. Immunopathology of hRSV infection: prospects for developing vaccines without this complication. Rev. Med. Virol. 17:5-34.
27. Wu, H., D. S. Pfarr, S. Johnson, Y. A. Brewah, R. M. Woods, N. K. Patel, W. I. White, J. F. Young, and P. A. Kiener. 2007. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368: 652-665.
28. Wyde, P. R., S. Laquerre, S. N. Chetty, B. E. Gilbert, T. J. Nitz, and D. C. Pevear. 2005. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 68:18-26.